KR970042511A - 아다만틸기를 함유하는 이방향족 화합물, 그를 함유하는 약약적 조성물 및 화장조성물 및 그의 용도 - Google Patents

아다만틸기를 함유하는 이방향족 화합물, 그를 함유하는 약약적 조성물 및 화장조성물 및 그의 용도 Download PDF

Info

Publication number
KR970042511A
KR970042511A KR1019960059986A KR19960059986A KR970042511A KR 970042511 A KR970042511 A KR 970042511A KR 1019960059986 A KR1019960059986 A KR 1019960059986A KR 19960059986 A KR19960059986 A KR 19960059986A KR 970042511 A KR970042511 A KR 970042511A
Authority
KR
South Korea
Prior art keywords
radical
adamantyl
radicals
benzoic acid
compound
Prior art date
Application number
KR1019960059986A
Other languages
English (en)
Other versions
KR100236848B1 (ko
Inventor
쟝-미셸 베르나르동
Original Assignee
슈르 브라암
쌍트르 앵떼르나 씨오날 드 로셰르슈 데르마똘로지끄 갈데르마
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 슈르 브라암, 쌍트르 앵떼르나 씨오날 드 로셰르슈 데르마똘로지끄 갈데르마 filed Critical 슈르 브라암
Publication of KR970042511A publication Critical patent/KR970042511A/ko
Application granted granted Critical
Publication of KR100236848B1 publication Critical patent/KR100236848B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/94—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of polycyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/60—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in meta- or para- positions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/56—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/56—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/20—Esters of monothiocarboxylic acids
    • C07C327/32—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/38—Amides of thiocarboxylic acids
    • C07C327/48—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
    • C07C65/28—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups having unsaturation outside the aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/32—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing keto groups
    • C07C65/40—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
    • C07D317/22—Radicals substituted by singly bound oxygen or sulfur atoms etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)

Abstract

본 발명은 하기 화학식 1을 갖는 신규한 이방향족 화합물 뿐만 아니라 인간 또는 가축용 의약의 사용을 목적으로 하는 약학적 조성물 또는 이외의 화장조성물에 관한 것이다.

Description

아다만틸기를 함유하는 이방향족 화합물, 그를 함유하는 약학적 조성물 및 화장조성물 및 그의 용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (29)

  1. 하기 화학식 1에 해당하는 이환식 방향족 화합물 및 그의 염 및 그의 광학 및 기하 이성질체:
    [화학식 1]
    [식중, R1은
    (ⅰ) -CH3라디칼,
    (ⅱ) -(CH2)n-O-R4라디칼,
    (ⅲ) -O-(CH2)m-(CO)n-R5라디칼,
    (ⅳ) -CO-R6라디칼,
    (ⅴ) -CO-O-R7라디칼을 나타내고,
    여기서 m 및 n 의 값, 및 R4- R7은 하기와 동일한 의미를 가지며, R2는 수소 또는 할로겐 원자, 탄소수 1 내지 20의 직쇄 또는 측쇄 알킬 라디칼, -OR4라디칼, 또는 -O-CH2-O-CH2-CH2-O-CH3라디칼을 나타내며, R3은
    (ⅰ) -Y-(CH2)p-Y-(CH2)q-R8라디칼,
    (ⅱ) -(CH2)p-Y-(CH2)q-R8라디칼,
    (ⅲ) -Y-(CH2)q-R8라디칼,
    (ⅳ) -CH=CH-(CH2)r-R8라디칼,
    (ⅴ) -(CH2)q-R8라디칼을 나타내고,
    여기서, p, q 및 r 의 값 및 Y 라디칼 및 R8은 하기 의미를 지니며, X 는 양방향으로 읽을 수 있는 하기 식(a) - (k) 의 연결을 나타내고:
    - Ar 은 하기 식 (a) - (f) 의 라디칼로부터 선택되는 라디칼을 나타내고,
    상기 설명 모두에서,
    m 은 1,2 또는 3의 정수이고, n 은 0 또는 1의 정수이고, p 는 1 내지 12의 정수이며, q 는 0 내지 12의 정수이고, r 은 0 내지 10의 정수이며, t 는 0, 1 또는 2에 해당하는 정수이고, Y는 산소원자 또는 S(O)t 라디칼을 나타내고, W는 산소원자, S(O)t 라디칼 또는 N-R10라디칼을 나타내며, R4는 수소원자, 저급 알킬 라디칼 또는 -CO-R11라디칼을 나타내고, R5는 저급알킬 또는 헤테로시클을 나타내며, R6은 수소원자, 저급 알킬 라디칼 또는라디칼(R' 및 R는 수소원자, 저급 알킬 라디칼, 모노- 또는 폴리히드록시알킬 라디칼, 선택적으로 치환된 아릴 라디칼 또는 아미노산 또는 펩티드 또는 당 잔기를 나타내거나, 또는 이외에 함께 헤테로시클을 형성한다)을 나타내며, R7은 수소원자, 탄소수 1 내지 20의 직쇄 또는 측쇄 알킬 라디칼, 알케닐 라디칼, 모노- 또는 폴리히드록시알킬 라디칼, 선택적으로 치환된 아릴 또는 아르알킬 라디칼 또는 당 잔기 또는 아미노산 또는 펩티드 잔기를 나타내고, R8은 동일하거나 상이하며, 수소원자, 탄소수 1 내지 20의 측쇄 알킬 라디칼, C3- C6시클로지방족 라디칼, 모노히드록시알킬 라디칼 또는 폴리히드록시알킬 라디칼 (히드록실은 선택적으로 메톡시 또는 아세톡시 또는 아세토니드형태로 보호된다), 아릴 라디칼, 알키닐 라디칼, -CO-R6라디칼, -CO-O-R7라디칼, 아민기가 하나 또는 둘의 저급 알킬기로 치환된 아미노알킬 라디칼, 헤테로시클, R7은 상기 의미와 동일한 헤테로시클을 나타내며, R9는 동일하거나 상이하며, 수소 또는 할로겐원자, 탄소수 1 내지 20의 직쇄 또는 측쇄 알킬 라디칼, -OR4라디칼 또는 -O-CH2-O-CH2-CH2-O-CH3라디칼을 나타내고, R10은 동일하거나 상이하며, 수소원자 또는 저급 알킬 라디칼을 나타내고, R11은 - X가 식(a), (b), (c), (g), (h), (j) 또는 (k)의 연결일 때, R3은 R8이 수소원자인 식 (ⅲ), (ⅳ) 또는 (ⅴ) 라디칼 이외의 것이고, - X가 식(a)의 연결일 때, R3은 라디칼 (ⅲ) 이외의 것이고, - X가 식(b)의 연결이고, R3은 Y가 황원자를 나타내는 식(ⅲ)의 라디칼을 나타낼 때, R8은 아릴 라디칼 이외의 것이며, - X가 식(g), (h), (j) 또는 (k)의 연결을 나타내고, R3은 식(ⅴ)의 라디칼을 나타낼 때, R8은 모노히드록시알킬 또는 폴리히드록시알킬 라디칼 이외의 것인 저급 알킬 라디칼을 나타낸다.
  2. 제1항에 있어서, 알칼리 금속 또는 알칼리 토금속, 또는 이외에 아연 또는 유기 아민의 염 형태임을 특징으로 하는 화합물.
  3. 제1항 또는 제2항에 있어서, 저급 알킬 라디칼이 메틸, 에틸, 이소프로필, 부틸, t-부틸, 헥실, 논일 및 도데실 라디칼로 이루어지는 군으로부터 선택됨을 특징으로 하는 화합물.
  4. 제1항 또는 제2항에 있어서, 탄소수 1 내지 20의 직쇄 또는 측쇄 알킬 라디칼이 메틸, 에틸, 프로필, 2-에틸헥실, 옥틸, 도데실, 헥사데실 및 옥타데실 라디칼로 이루어지는 군으로부터 선택됨을 특징으로 하는 화합물.
  5. 제1항 또는 제2항에 있어서, 모노히드록시알킬 라디칼은 2-히드록시에틸, 2-히드록시프로필 및 3-히드록시프로필 라디칼로 이루어지는 군으로부터 선택됨을 특징으로 하는 화합물.
  6. 제1항 또는 제2항에 있어서, 폴리히드록시알킬 라디칼이 2,3-디히드록시프로필, 2,3,4-트리히드록시부틸 및 2,3,4,5-테트라히드록시펜틸 라디칼 또는 펜타에리트리톨 잔기로 이루어지는 군으로부터 선택됨을 특징으로 하는 화합물.
  7. 제1항 또는 제2항에 있어서, 아릴 라디칼이 하나 이상의 할로겐 원자, 하나 이상의 히드록실 또는 하나 이상의 니트로 반응기로 선택적으로 치환된 페닐 라디칼임을 특징으로 하는 화합물.
  8. 제1항 또는 제2항에 있어서, 아르알킬 라디칼이 하나 이상의 할로겐 원자, 하나 이상의 히드록실 또는 하나 이상의 니트로 반응기로 선택적으로 치환된 벤질 또는 펜에틸 라디칼로 이루어지는 군으로부터 선택됨을 특징으로 하는 화합물.
  9. 제1항 또는 제2항에 있어서, 알케닐 라디칼이 탄소수 1 내지 5 및 하나 이상의 에틸렌 불포화물을 함유하는 라디칼로 이루어지는 군으로부터 선택됨을 특징으로 하는 화합물.
  10. 제1항 또는 제2항에 있어서, 당 잔기는 글루코스, 갈라토스, 만노스 및 글루크론산 잔기로 이루어지는 군으로부터 선택됨을 특징으로 하는 화합물.
  11. 제1항 또는 제2항에 있어서, 아미노산 잔기가 리신, 글리신 또는 아스파르트산 유래의 잔기로 이루어지는 군으로부터 선택됨을 특징으로 하는 화합물.
  12. 제1항 또는 제2항에 있어서, 펩티드 잔기가 디펩티드 또는 트리펩티드 잔기로 이루어지는 군으로부터 선택됨을 특징으로 하는 화합물.
  13. 제1항 또는 제2항에 있어서, 헤테로시클릭 라디칼이 C1- C6알킬 또는 모노- 또는 폴리히드록시알킬 라디칼로 4-위치에서 선택적으로 치환된, 피페리디노, 모르폴리노, 피롤리디노 또는 피페라지노 라디칼로 이루어지는 군으로부터 선택됨을 특징으로 하는 화합물.
  14. 제1항 또는 제2항에 있어서, 할로겐 원자가 불소, 염소 또는 브롬으로 이루어지는 군으로부터 선택됨을 특징으로 하는 화합물.
  15. 제1항 또는 제2항에 있어서, 탄소수 1 내지 20의 측쇄 알킬 라디칼은 2-메틸부틸, 2-메틸펜틸, 1-메틸헥실 및 3-메틸헵틸 라디칼로부터 선택됨을 특징으로 하는 화합물.
  16. 제1항 또는 제2항에 있어서, 아미노 알킬 라디칼이 아미노메틸, 3-아미노프로필 및 6-아미노헥실 라디칼로부터 선택됨을 특징으로 하는 화합물.
  17. 제1항 또는 제2항에 있어서, 알키닐 라디칼이 탄소수 2 내지 6의 알키닐 라디칼임을 특징으로 하는 화합물.
  18. 제1항 또는 제2항에 있어서, 탄소수 3 내지 6의 시클로지방족 라디칼이 시클로프로필 및 시클로헥실 라디칼로부터 선택됨을 특징으로 하는 화합물.
  19. 제1항에 있어서, 하기로 이루어지는 군으로부터 단독 또는 혼합물의 형태로 선택됨을 특징으로 하는 화합물:
    4-[3-(1-아다만틸)-4-메톡시페닐티오메틸]벤조산
    4-[3-(1-아다만틸)-4-메톡시페닐술피닐메틸]벤조산
    4-[3-(1-아다만틸)-4-메톡시페닐메틸술포닐]벤조산
    4-[3-(1-아다만틸)-4-메톡시페닐메틸술피닐]벤조산
    4-[3-(1-아다만틸)-4-메톡시페닐술포닐메틸]벤조산
    4-[3-(1-아다만틸)-4-메톡시페닐티오카르복스아미도]벤조산
    4-[3-(1-아다만틸)-4-메톡시페닐메틸티오]벤조산
    4-[3-(1-아다만틸)-4-메톡시페닐메틸아미노]벤조산
    4-[[3-옥소-3[3-(1-아다만틸)-4-메톡시페닐]-1-프로피닐]]벤조산
    4-[3-(1-아다만틸)-4-메톡시에톡시메톡시벤즈아미도]벤조산
    4-[3-(1-아다만틸)-4-메톡시에톡시메톡시벤조일옥시]벤조산
    (E)-4-[[3-옥소-3[3-(1-아다만틸)-4-메톡시에톡시메톡시페닐]-1-프로피닐]]벤조산
    4-[[3-히드록시-3[3-(1-아다만틸)-4-메톡시에톡시메톡시페닐]-1-프로피닐]]벤조산
    4-[3-(1-아다만틸)-4-(2,2-디메틸-1,3-디옥소란-4-메틸옥시)페닐카르복스아미도]벤조산
    4-[3-(1-아다만틸)-4-(2,3-디히드록시프로필옥시)페닐카르복스아미도]벤조산
    2-[3-(1-아다만틸)-4-메톡시페녹시메틸]-4-티오펜카르복실산
    2-[3-(1-아다만틸)-4-메톡시페닐아미노메틸]-4-티오펜카르복실산
    2-[3-(1-아다만틸)-4-메톡시페닐티오메틸]-4-티오펜카르복실산
    4-[3-(1-아다만틸)-4-(2,2-디메틸-1,3-디옥소란-4-메틸옥시)벤조일옥시]벤조산
    4-[3-히드록시-3[5-(1-아다만틸)-2,4-디메톡시에톡시메톡시페닐]-1-프로피닐]벤조산
    4-[3-(1-아다만틸)-4-메톡시에톡시메톡시벤조일티오]벤조산
    N-메틸-4-[3-(1-아다만틸)-4-메톡시에톡시메톡시페닐카르복스아미도]벤조산
    4-[3-(1-아다만틸)-4-메톡시에톡시메톡시페닐티오카르복스아미도]벤조산
    (E)-4-[[3-옥소-3[3-(1-아다만틸)-4-메톡시메톡시페닐]-1-프로페닐]]벤조산
    (E)-4-[[3-옥소-3[3-(1-아다만틸)-4-히드록시페닐]-1-프로페닐]]벤조산
    (E)-4-[[3-옥소-3[3-(1-아다만틸)-4-메톡시페닐]-1-프로페닐]]벤조산
    (E)-4-[[3-옥소-3[3-(1-아다만틸)-4-(3-히드록시프로필옥시)페닐]-1-프로페닐]]벤조산
    4-[3-(1-아다만틸)-4-메톡시에톡시메톡시벤조일옥시]벤즈알데히드
    4-[3-(1-아다만틸)-4-메톡시에톡시메톡시벤조일옥시]벤젠메탄올
    (E)-N-에틸-4-[[3-옥소-3-[3-(1-아다만틸)-4-메톡시에톡시메톡시페닐]-1-프로페닐]]벤즈아미드
    (E)-N-(4-히드록시페닐)-4-[[3-옥소-3-[3-(1-아다만틸)-4-메톡시에톡시메톡시페닐]-1-프로페닐]]벤즈아미드
    (E)-4-[[3-옥소-3-[3-(1-아다만틸)-4-메톡시에톡시메톡시페닐]-1-프로페닐]]페놀
  20. 제1항에 있어서, 하나 이상의 하기 특성을 가짐을 특징으로 하는 화합물:
    R1은 -COO-R7또는 -CO-R6라디칼, R3은 -Y-(CH2)p-Y-(CH2)q-R8, (CH2)p-(Y)n-(CH2)q-R8또는 -Y-(CH2)q-R8, X는 식(a), (e), (f), (j) 또는 (k)의 연결을 나타냄. Ar은 식(a) 또는 식(b)의 라디칼을 나타냄.
  21. 의약 제품으로서 사용되는 제1항 내지 제20항 중 어느 한 항에 따른 화합물.
  22. 제21항에 있어서, 피부병, 류마티스, 호흡기, 심폐 및 안 질환자의 치료를 목적으로 하는 의약 제품으로 사용되는 화합물.
  23. 피부병, 류마티스, 호흡기, 심폐 및 안 질환자의 치료를 목적으로 하는 의약 제품의 제조에 사용되는 제1항 내지 제20항에서 정의된 하나 이상의 화합물.
  24. 약학적으로 허용 가능한 담체에, 제1항 내지 제20항 중 어느 한 항에서 정의된 하나 이상의 화합물을 함유함을 특징으로 하는 약학적 조성물.
  25. 제24항에 있어서, 제1항 내지 제16항 중 어느 한 항에 따른 화합물의 농도가 전체 조성물에 대하여 0.001 - 5 중량%임을 특징으로 하는 조성물.
  26. 화장품으로 허용 가능한 담체에, 제1항 내지 제20항 중 어느 한 항에서 정의된 하나 이상의 화합물을 함유함을 특징으로 하는 화장 조성물.
  27. 제26항에 있어서, 제1항 내지 제20항 중 어느 한 항에 따른 화합물의 농도가 전체 조성물에 대하여 0.001 - 3 중량%임을 특징으로 하는 조성물.
  28. 신체 또는 모발 보건에 사용되는 제26항 또는 제27항에서 정의된 화장 조성물.
  29. 제9항에 있어서, 알케닐 라디칼이 알릴 라디칼임을 특징으로 하는 화장 조성물
KR1019960059986A 1995-12-01 1996-11-29 아다만틸기를 함유하는 이방향족 화합물, 그를함유하는 약학적 조성물 및 화장 조성물, 및 그의 용도 KR100236848B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR95-14260 1995-12-01
FR9514260A FR2741878B1 (fr) 1995-12-01 1995-12-01 Composes biaromatiques portant un groupement adamantyl en ortho, compositions pharmaceutiques et cosmetiques les contenant et utilisations

Publications (2)

Publication Number Publication Date
KR970042511A true KR970042511A (ko) 1997-07-24
KR100236848B1 KR100236848B1 (ko) 2000-03-02

Family

ID=9485079

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960059986A KR100236848B1 (ko) 1995-12-01 1996-11-29 아다만틸기를 함유하는 이방향족 화합물, 그를함유하는 약학적 조성물 및 화장 조성물, 및 그의 용도

Country Status (23)

Country Link
US (1) US5786379A (ko)
EP (1) EP0776885B1 (ko)
JP (1) JP2733053B2 (ko)
KR (1) KR100236848B1 (ko)
AR (1) AR005241A1 (ko)
AT (1) ATE186049T1 (ko)
AU (1) AU693046B2 (ko)
BR (1) BR9604632A (ko)
CA (1) CA2191789C (ko)
DE (1) DE69604889T2 (ko)
DK (1) DK0776885T3 (ko)
ES (1) ES2142034T3 (ko)
FR (1) FR2741878B1 (ko)
GR (1) GR3031843T3 (ko)
HU (1) HUP9603295A3 (ko)
IL (1) IL119640A (ko)
MX (1) MX9605940A (ko)
NO (1) NO307925B1 (ko)
NZ (1) NZ299787A (ko)
PL (1) PL185512B1 (ko)
PT (1) PT776885E (ko)
RU (1) RU2138474C1 (ko)
ZA (1) ZA969716B (ko)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2755011B1 (fr) * 1996-10-31 1998-11-20 Cird Galderma Utilisation des inhibiteurs de l'activite de l'acide retinoique pour traiter les peaux sensibles et/ou les dommages aigus induits par les rayonnements u.v.
FR2757852B1 (fr) 1996-12-31 1999-02-19 Cird Galderma Composes stilbeniques a groupement adamantyl, compositions les contenant et utilisations
FR2763588B1 (fr) * 1997-05-23 1999-07-09 Cird Galderma Composes triaromatiques, compositions les contenant et utilisations
FR2776659B1 (fr) * 1998-03-31 2000-05-26 Cird Galderma Nouveaux composes heteroethynylenes et compositions pharmaceutiques et cosmetiques les contenant
US6436993B1 (en) * 1999-07-13 2002-08-20 The Salk Institute For Biological Studies Use of RAR antagonists as modulators of hormone mediated processes
US7598278B2 (en) * 2002-04-11 2009-10-06 L'oreal Administration of pyridinedicarboxylic acid compounds for stimulating or inducing the growth of human keratinous fibers and/or arresting their loss
CA2485589A1 (en) * 2002-05-14 2003-11-27 Baylor College Of Medicine Small molecule inhibitors of her2 expression
US7449480B2 (en) * 2002-05-14 2008-11-11 Baylor College Of Medicine Small molecule inhibitors of HER2 expression
GB0302094D0 (en) 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
GB0324269D0 (en) 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
WO2006040329A1 (en) * 2004-10-12 2006-04-20 Novo Nordisk A/S 1 ibeta- hydroxysteroid dehydrogenase type 1 active spiro compounds
US20060235028A1 (en) * 2005-04-14 2006-10-19 Li James J Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
KR100682549B1 (ko) 2005-07-26 2007-02-15 (주)아모레퍼시픽 세사몰 유도체 및 그의 제조방법
JP4915064B2 (ja) * 2005-08-24 2012-04-11 住友ベークライト株式会社 カルボン酸化合物およびその誘導体
KR20080069189A (ko) * 2005-11-01 2008-07-25 트랜스테크 파르마, 인크. 치환된 아미드의 약학적 사용
AU2006310518A1 (en) * 2005-11-01 2007-05-10 High Point Pharmaceuticals, Llc Pharmaceutical use of substituted amides
WO2007107550A1 (en) * 2006-03-21 2007-09-27 High Point Pharmaceuticals, Llc Adamantane derivatives for the treatment of the metabolic syndrome
AU2007236049A1 (en) 2006-04-07 2007-10-18 High Point Pharmaceuticals, Llc 11beta-hydroxysteroid dehydrogenase type 1 active compounds
JP2009539937A (ja) * 2006-06-16 2009-11-19 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー 置換型ピペリジンカルボキサミドの医薬的使用
CA2657078A1 (en) * 2006-07-13 2008-01-17 High Point Pharmaceuticals, Llc 11beta-hydroxysteroid dehydrogenase type 1 active compounds
EP1878721A1 (en) * 2006-07-13 2008-01-16 Novo Nordisk A/S 4-Piperidylbenzamides as 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
FR2910321B1 (fr) 2006-12-21 2009-07-10 Galderma Res & Dev S N C Snc Gel creme comprenant au moins un retinoide et du peroxyde de benzole
EP2518063B1 (en) * 2006-12-21 2017-02-01 Sloan-Kettering Institute For Cancer Research Pyridazinones and furan-containing compounds
FR2910320B1 (fr) 2006-12-21 2009-02-13 Galderma Res & Dev S N C Snc Emulsion comprenant au moins un retinoide et du peroxyde de benzole
WO2008101907A2 (en) * 2007-02-23 2008-08-28 High Point Pharmaceuticals, Llc N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase
WO2008101885A1 (en) * 2007-02-23 2008-08-28 High Point Pharmaceuticals, Llc N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase
BRPI0806847A2 (pt) 2007-02-23 2014-04-29 High Point Pharmaceuticals Llc N-adamantil benzamidas como inibidores de 11-beta-hidroxiesteróide desidrogenase
EP2125704A1 (en) * 2007-02-23 2009-12-02 High Point Pharmaceuticals, LLC N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase
AU2007349112A1 (en) * 2007-03-09 2008-09-18 High Point Pharmaceuticals, Llc Indole- and benzimidazole amides as hydroxysteroid dehydrogenase inhibitors
JP2010522766A (ja) * 2007-03-28 2010-07-08 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー １１ベータ−ｈｓｄ１活性化合物
WO2008127924A1 (en) * 2007-04-11 2008-10-23 High Point Pharmaceuticals, Llc. Novel compounds
CA2685036A1 (en) * 2007-04-24 2008-11-06 High Point Pharmaceuticals, Llc Pharmaceutical use of substituted amides
FR2931661B1 (fr) 2008-05-30 2010-07-30 Galderma Res & Dev Nouvelles compositions depigmentantes sous forme d'une composition anhydre sans vaseline et sans elastomere comprenant un derive phenolique solubilise et un retinoide.
KR20110088575A (ko) * 2008-11-21 2011-08-03 하이 포인트 파마슈티칼스, 엘엘씨 아다만틸 벤즈아미드 화합물
US8513430B2 (en) 2010-07-27 2013-08-20 High Point Pharmaceuticals, Llc Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta HSD1 modulators
KR101604053B1 (ko) * 2011-08-05 2016-03-16 (주)아모레퍼시픽 신규 벤조산아미드 화합물
FR3030248B1 (fr) 2014-12-22 2018-03-23 L'oreal Association derive d'acide pyridine-dicarboxylique/agent anti-oxydant particulier
EP4037672A1 (en) 2019-10-02 2022-08-10 Institut National de la Santé et de la Recherche Médicale (INSERM) Use of retinoic acid receptor (rar) agonists for reversing, preventing, or delaying calcification of aortic valve

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU86258A1 (fr) * 1986-01-21 1987-09-03 Rech Dermatologiques C I R D S Composes benzamido aromatique,leur procede de preparation et leur utilisation en medecine humaine ou veterinaire et en cosmetique
LU86387A1 (fr) * 1986-04-04 1987-12-07 Oreal Composes aromatiques,leur procede de preparation et leur utilisation en medicine humaine et veterinaire et en cosmetique
LU87109A1 (fr) * 1988-01-20 1989-08-30 Cird Esters et thioesters aromatiques,leur procede de preparation et leur utilisation en medecine humaine ou veterinaire et en cosmetique
FR2649977B1 (fr) * 1989-07-18 1991-10-04 Cird Esters bi-aromatiques, leur procede de preparation et leur utilisation en medecine humaine ou veterinaire et en cosmetique
FR2650824B1 (fr) * 1989-07-18 1993-01-22 Cird Thioesters bi-aromatiques, leur procede de preparation et leur utilisation en medecine humaine ou veterinaire et en cosmetique
LU87821A1 (fr) * 1990-10-12 1992-05-25 Cird Galderma Composes bi-aromatiques,et leur utilisation en medecine humaine et veterinaire et en cosmetique
US5466861A (en) * 1992-11-25 1995-11-14 Sri International Bridged bicyclic aromatic compounds and their use in modulating gene expression of retinoid receptors
FR2713640B1 (fr) * 1993-12-15 1996-01-05 Cird Galderma Nouveaux composés aromatiques polycycliques, compositions pharmaceutiques et cosmétiques les contenant et utilisations.
FR2719044B1 (fr) * 1994-04-26 1996-05-31 Cird Galderma Nouveaux composés bi-aromatiques acétylénés à groupement adamantyle, compositions pharmaceutiques et cosmétiques les contenant et utilisations.
US5498795A (en) * 1994-12-29 1996-03-12 Allergan, Inc. Acetylenes disubstituted with hydroxyaryl and aryl or heteroaryl groups having retinoid-like biological activity

Also Published As

Publication number Publication date
NO307925B1 (no) 2000-06-19
JPH09221442A (ja) 1997-08-26
AR005241A1 (es) 1999-04-28
CA2191789A1 (fr) 1997-06-02
ES2142034T3 (es) 2000-04-01
EP0776885A1 (fr) 1997-06-04
FR2741878B1 (fr) 1998-01-09
BR9604632A (pt) 1998-06-23
EP0776885B1 (fr) 1999-10-27
PL317277A1 (en) 1997-06-09
NZ299787A (en) 1998-05-27
IL119640A (en) 2001-09-13
DK0776885T3 (da) 2000-03-27
KR100236848B1 (ko) 2000-03-02
DE69604889D1 (de) 1999-12-02
PL185512B1 (pl) 2003-05-30
RU2138474C1 (ru) 1999-09-27
DE69604889T2 (de) 2000-02-03
IL119640A0 (en) 1997-02-18
GR3031843T3 (en) 2000-02-29
FR2741878A1 (fr) 1997-06-06
US5786379A (en) 1998-07-28
MX9605940A (es) 1998-04-30
NO965103D0 (no) 1996-11-29
AU693046B2 (en) 1998-06-18
HU9603295D0 (en) 1997-01-28
AU7187296A (en) 1997-06-12
NO965103L (no) 1997-06-02
PT776885E (pt) 2000-04-28
ATE186049T1 (de) 1999-11-15
ZA969716B (en) 1997-06-18
CA2191789C (fr) 2001-02-20
HUP9603295A3 (en) 1997-11-28
HUP9603295A2 (en) 1997-05-28
JP2733053B2 (ja) 1998-03-30

Similar Documents

Publication Publication Date Title
KR970042511A (ko) 아다만틸기를 함유하는 이방향족 화합물, 그를 함유하는 약약적 조성물 및 화장조성물 및 그의 용도
RU96123243A (ru) Биароматические соединения с адамантильной группой, фармацевтические и косметические композиции на их основе
KR950029244A (ko) 신규한 폴리엔계 화합물, 그를 함유하는 약제학 및 미용상의 조성물 및 용도
KR970042508A (ko) 이방향족 화합물, 그를 함유하는 약학적 조성물 및 화장 조성물, 및 그의용도
KR950017878A (ko) 이 방향족 프로피닐 화합물, 그를 함유하는 약학적 및 화장품 조성물 및 그의 용도
RU96108398A (ru) Применение ретиноидов в косметической или фармацевтической композиции, соединения
DE69926058D1 (de) Polyaminosäurederivate und ihre verwendung in zusammensetzungen zur behandlung von keratinischen fasern
TW200472B (ko)
JP5746864B2 (ja) シワ改善剤
KR920021578A (ko) 포스프노/비아릴 치환된 디펩티드 유도체
FR2833949A1 (fr) NOUVEAUX LIGANDS ACTIVATEURS DES RECEPTEURS PPARy, LEUR PROCEDE DE PREPARATION ET LEUR UTILISATION EN MEDECINE HUMAINE AINSI QU'EN COSMETIQUE
US6384025B2 (en) Retinyl carbonate derivatives, preparation process and uses
RU96122858A (ru) Биароматические соединения и фармацевтические и косметические композиции на их ос основе
KR20130050395A (ko) 히스톤 데아세틸라제(ｈｄａｃ) 저해제를 레티노이드와 함께 포함하는 조성물
DE69125216T2 (de) Aminoalkanesulfonsäurederivate und pharmazeutische Zusammensetzungen davon zur Prävention oder Behandlung von Herzerkrankungen
CA2545296A1 (en) Biphenyl derivatives useful as ligands that activate the rar receptors, process for preparing them and use thereof in human medicine and in cosmetics
KR950029242A (ko) 2환-방향족 화합물, 이를 함유하는 제약 및 화장품 조성물 및 이의 용도
KR870005986A (ko) 방향족 티오에테르 및 이의 제조방법
FR2713637B1 (fr) Nouveaux composés bi-aromatiques dérivés d'amide, compositions pharmaceutiques et cosmétiques les contenant et utilisations.
RU99104819A (ru) Биароматические соединения и фармацевтические и косметические композиции, включающие их
EP0679631A1 (fr) Composés bi-aromatiques acétylénés à groupement adamantyle, compositions pharmaceutiques et cosmétiques les contenant et utilisations
US20060269498A1 (en) Hair shaping composition comprising at least one polyguanidine other than hydroxide
JPH11500747A (ja) サブスタンスｐアンタゴニストまたはｃｇｒｐアンタゴニストを含有するケラチン繊維のパーマネント変形のための組成物
AU675902B2 (en) Photocleavable metal-chelating agents and compositions containing them
JP2000239245A (ja) フェノールアミンのヒドロキシマンデル酸アミド

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
J201 Request for trial against refusal decision
B701 Decision to grant
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20120924

Year of fee payment: 14

LAPS Lapse due to unpaid annual fee